HomeAI · summaries
Storia in 2 fonti
UK biotech secures $115M to advance portfolio of virus-targeting antibodies
RQ Bio has clinched $115 million in a Series A raise to advance a preclinical pipeline of virus-targeting antibodies.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Investors pour $115M into RQ Bio in search of a preventive flu drug
The startup claims to have a “differentiated” antibody that can provide long-lasting protection against a variety of influenza strains.
- ·
endpoints.news
UK biotech secures $115M to advance portfolio of virus-targeting antibodies
RQ Bio has clinched $115 million in a Series A raise to advance a preclinical pipeline of virus-targeting antibodies.